Update regarding Renalytix AI PLC

 1st Jun 2018


Download full announcement


Further to the Company’s announcement of 31 May 2018, regarding the exclusive license and collaboration agreement (the “Agreement”) with Icahn School of Medicine at Mount Sinai in New York, USA (“Mount Sinai”), EKF, the AIM listed point-of-care business, confirms that Renalytix AI PLC has undertaken a share subscription which is expected to conclude in the coming days (the “Subscription”).  Renalytix AI PLC is a newly incorporated company which is party to the Agreement.  The Subscription reflects the involvement of the parties involved in building the Renalytix AI business to date and is an intermediate step in the structuring the Renalytix AI business for separate funding as previously disclosed.  


Upon conclusion of the additional funding for Renalytix AI PLC, that entity is expected to acquire the equity of Renalytix AI Inc, the EKF group company which holds the Company’s licence to the sTNFR biomarker technology, in a share-for-share exchange (the “Renalytix AI Combination”).  Following the Subscription and pro forma for the Renalytix AI Combination, the major shareholders in Renalytix AI PLC are expected to be as follows, before taking into account the effects of any additional equity funding:


EKF Diagnostics Holdings plc


Mount Sinai


Renwick Capital LLC(1)


Julian Baines(2)


Richard Evans(3)


Fergus Fleming(4)








(1) Adviser to EKF on the Renalytix AI opportunity, controlled by James McCullough and James Sterling

(2) CEO of EKF and current Executive Chairman of Renalytix AI PLC

(3) CFO of EKF and Non-Executive Director of Renalytix AI PLC

(4) A consultant to EKF on the sTNFR technology and proposed CTO of Renalytix AI PLC


Further announcements will be made as appropriate.



EKF Diagnostics Holdings plc
Julian Baines, CEO
Richard Evans, Finance Director and COO
00 44 29 2071 0570
N+1 Singer
Alex Price / Shaun Dobson
00 44 20 7496 3000

Walbrook PR Limited
Paul McManus
Lianne Cawthorne

00 44 20 7933 8780 or ekf@walbrookpr.com
00 44 7980 541 893
00 44 7584 391 303